Xilis Inc. added $19 million to its series A financing round, bringing the total amount raised to over $89 million. FPV Ventures led the extension, with participation from Alexandria Venture Investments and EQT Life Sciences, Mubadala Capital Management, Pear Ventures, GV, the Duke Angel Network, Catalio Capital Management, Two Sigma Ventures, Felicis Ventures and Alix Ventures.
Helixon Ltd. raised ¥500 million (US$75 million) in a series A round for its artificial intelligence (AI) drug development platform. The Beijing-based company is building a next-generation AI computing platform by combining it with self-developed high-throughput experimental technologies, aiming to provide drug developers with an intelligent system for molecular computation, simulation and design.
Kranus Health GmbH has raised $6.5 million in series A funding to ramp commercialization of its digital therapy for treating erectile dysfunction (ED). Eleven European investors participated in this fundraising. The round was led by early-stage health care venture capitalists Karista SAS, while Peak Pride Management GmbH also joined the funding round.
Helixon Ltd. raised ¥500 million (US$75 million) in a series A round for its artificial intelligence (AI) drug development platform. The Beijing-based company is building a next-generation AI computing platform by combining it with self-developed high-throughput experimental technologies, aiming to provide drug developers with an intelligent system for molecular computation, simulation and design.
Two Israeli companies aiming to improve in vitro fertilization (IVF) success rates received good news recently, with Aivf Ltd. hauling in $25 million in a series A round for Ema, its IVF software platform, and Fairtility Ltd. gaining CE mark for its CHLOE EQ embryo quality decision-support tool.
Tessa Therapeutics Ltd. has a closed a $126 million series A financing round to advance its ongoing clinical development, which includes the initiation of a pivotal trial of autologous CD30-CAR-T therapy (TT-11) and advancement of allogeneic CD30.CAR EBVST therapy (TT-11X) programs.
Investors ate up the opportunity to be part of Gemelli Biotech Corp.’s series A funding round, which raised $19 million to support the company’s growth and expand access to its diagnostic tests for gastrointestinal (GI) diseases. Blue Ox Healthcare Partners led the round with founding investor Cedars-Sinai and support from Carolina Angel Network, Cerracap Ventures and several family offices.
Although there has been huge progress in treatment of cystic fibrosis over the last decade, with Vertex Pharmaceuticals Inc. becoming the first to address the underlying cause of the disease with its Kalydeco (ivacaftor), approved in 2012, there are still many patients who aren’t eligible for treatment.
Tessa Therapeutics Ltd. has a closed a $126 million series A financing round to advance its ongoing clinical development, which includes the initiation of a pivotal trial of autologous CD30-CAR-T therapy (TT-11) and advancement of allogeneic CD30.CAR EBVST therapy (TT-11X) programs.
RSS
